TY - JOUR
T1 - Clinical significance of various drug-sensitivity markers in patients with surgically resected pulmonary pleomorphic carcinoma
AU - Imai, Hisao
AU - Shimizu, Kimihiro
AU - Kawashima, Osamu
AU - Endoh, Hideki
AU - Imaizumi, Kazuyoshi
AU - Goto, Yasuhiro
AU - Kamiyoshihara, Mitsuhiro
AU - Sugano, Masayuki
AU - Yamamoto, Ryohei
AU - Tanaka, Shigebumi
AU - Fujita, Atsushi
AU - Kogure, Yoshihito
AU - Seki, Yukio
AU - Mogi, Akira
AU - Oyama, Tetsunari
AU - Minato, Koichi
AU - Asao, Takayuki
AU - Kaira, Kyoichi
N1 - Publisher Copyright:
© 2019 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2019/11
Y1 - 2019/11
N2 - Various drug-sensitivity markers are potentially responsible for tumor progression and chemotherapy resistance in cancer patients with both epithelial and sarcomatous components; however, the clinicopathological significance of drug-sensitivity markers in patients with pulmonary pleomorphic carcinoma (PPC) remains unknown. Here, we clarified the prognostic impact of these drug-sensitivity markers in PPC by performing immunohistochemical and clinicopathologic analyses of samples from 105 patients with surgically resected PPC in order to evaluate levels of vascular endothelial growth factor 2 (VEGFR2), stathmin 1 (STMN1), tubulin β3 class III (TUBB3), thymidylate synthetase (TS), topoisomerase II (Topo-II), glucose-regulated protein, and 78 kDa (GRP78)/binding immunoglobulin protein (BiP). We observed the rates of high expression for VEGFR2, STMN1, TUBB3, TS, Topo-II, and GRP78/BiP were 33% (39/105), 35% (37/105), 61% (64/105), 51% (53/105), 31% (33/105), and 51% (53/105) of the samples, respectively. Moreover, multivariate analysis identified VEGFR2 and GRP78/BiP as significant independent markers for predicting worse prognosis. These findings suggested elevated VEGFR2 and decreased GRP78/BiP levels as independent factors for predicting poor outcomes following surgical resection in patients with PPC.
AB - Various drug-sensitivity markers are potentially responsible for tumor progression and chemotherapy resistance in cancer patients with both epithelial and sarcomatous components; however, the clinicopathological significance of drug-sensitivity markers in patients with pulmonary pleomorphic carcinoma (PPC) remains unknown. Here, we clarified the prognostic impact of these drug-sensitivity markers in PPC by performing immunohistochemical and clinicopathologic analyses of samples from 105 patients with surgically resected PPC in order to evaluate levels of vascular endothelial growth factor 2 (VEGFR2), stathmin 1 (STMN1), tubulin β3 class III (TUBB3), thymidylate synthetase (TS), topoisomerase II (Topo-II), glucose-regulated protein, and 78 kDa (GRP78)/binding immunoglobulin protein (BiP). We observed the rates of high expression for VEGFR2, STMN1, TUBB3, TS, Topo-II, and GRP78/BiP were 33% (39/105), 35% (37/105), 61% (64/105), 51% (53/105), 31% (33/105), and 51% (53/105) of the samples, respectively. Moreover, multivariate analysis identified VEGFR2 and GRP78/BiP as significant independent markers for predicting worse prognosis. These findings suggested elevated VEGFR2 and decreased GRP78/BiP levels as independent factors for predicting poor outcomes following surgical resection in patients with PPC.
UR - http://www.scopus.com/inward/record.url?scp=85074225220&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85074225220&partnerID=8YFLogxK
U2 - 10.3390/cancers11111636
DO - 10.3390/cancers11111636
M3 - Article
AN - SCOPUS:85074225220
SN - 2072-6694
VL - 11
JO - Cancers
JF - Cancers
IS - 11
M1 - 1636
ER -
